Endocrinology, Vol 126, 1449-1456, Copyright © 1990 by Endocrine Society

ARTICLES

The stimulation of uterine complement component C3 gene expression by antiestrogens

SA Sundstrom, BS Komm, Q Xu, V Boundy and CR Lyttle
Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia 19104.

We have previously demonstrated that complement component C3 is regulated by estradiol in the rat uterus. The antiestrogens tamoxifen, LY117018, and LY156758 exert both agonist and antagonist effects on the immature rat uterus. In this study, these three antiestrogens also stimulated an increase in the synthesis and secretion of C3. The combination of LY117018 and estradiol did not increase C3 to a greater extent than LY117018 alone, which suggests a similar mechanism of regulation. The regulation may be transcriptional since both estradiol and tamoxifen increase the concentration of C3 mRNA. Results of in situ hybridization revealed that the increase in C3 mRNA occurred in the luminal epithelial cells. Although the induction by estradiol and the antiestrogens was similar in most aspects, the time course for tamoxifen-stimulated synthesis differed from estradiol in that the time required to achieve maximal concentrations of C3 was delayed by 12 h with tamoxifen. This pattern did not appear to be related to the time it took to convert tamoxifen to 4-hydroxytamoxifen since the C3 response for these antiestrogens were identical. The antiestrogen- stimulated increase in C3 synthesis and mRNA concentration was prevented by the co-administration of progesterone lending support to the hypothesis that the antiestrogens regulate C3 synthesis via a mechanism similar to estrogen.

This article has been cited by other articles:

				P. Yi, S. Bhagat, R. Hilf, R. A. Bambara, and M. Muyan Differences in the Abilities of Estrogen Receptors to Integrate Activation Functions Are Critical for Subtype-Specific Transcriptional Responses Mol. Endocrinol., August 1, 2002; 16(8): 1810 - 1827. [Abstract] [Full Text] [PDF]

				J. M. Schafer, H. Liu, D. J. Bentrem, J. W. Zapf, and V. C. Jordan Allosteric Silencing of Activating Function 1 in the 4-Hydroxytamoxifen Estrogen Receptor Complex Is Induced by Substituting Glycine for Aspartate at Amino Acid 351 Cancer Res., September 1, 2000; 60(18): 5097 - 5105. [Abstract] [Full Text]

				D. S. Hunter, L. C. Hodges, P. M. Vonier, R. Fuchs-Young, M. M. Gottardis, and C. L. Walker Estrogen Receptor Activation via Activation Function 2 Predicts Agonism of Xenoestrogens in Normal and Neoplastic Cells of the Uterine Myometrium Cancer Res., July 1, 1999; 59(13): 3090 - 3099. [Abstract] [Full Text] [PDF]

				K. J. Modarress, J. Opoku, M. Xu, N. J. Sarlis, and S. S. Simons Jr. Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity J. Biol. Chem., September 19, 1997; 272(38): 23986 - 23994. [Abstract] [Full Text] [PDF]